|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHX8 |
Gene summary for DHX8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHX8 | Gene ID | 1659 |
| Gene name | DEAH-box helicase 8 | |
| Gene Alias | DDX8 | |
| Cytomap | 17q21.31 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | B7Z8F4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1659 | DHX8 | LZE4T | Human | Esophagus | ESCC | 4.62e-07 | 2.98e-01 | 0.0811 |
| 1659 | DHX8 | LZE7T | Human | Esophagus | ESCC | 1.52e-02 | 2.86e-01 | 0.0667 |
| 1659 | DHX8 | LZE8T | Human | Esophagus | ESCC | 2.61e-04 | 9.14e-02 | 0.067 |
| 1659 | DHX8 | LZE20T | Human | Esophagus | ESCC | 2.26e-04 | 8.88e-02 | 0.0662 |
| 1659 | DHX8 | LZE24T | Human | Esophagus | ESCC | 1.20e-12 | 2.78e-01 | 0.0596 |
| 1659 | DHX8 | P1T-E | Human | Esophagus | ESCC | 1.50e-02 | 1.77e-01 | 0.0875 |
| 1659 | DHX8 | P2T-E | Human | Esophagus | ESCC | 5.44e-15 | 2.75e-01 | 0.1177 |
| 1659 | DHX8 | P4T-E | Human | Esophagus | ESCC | 2.24e-12 | 2.57e-01 | 0.1323 |
| 1659 | DHX8 | P5T-E | Human | Esophagus | ESCC | 1.12e-10 | 3.06e-01 | 0.1327 |
| 1659 | DHX8 | P8T-E | Human | Esophagus | ESCC | 2.05e-17 | 3.35e-01 | 0.0889 |
| 1659 | DHX8 | P9T-E | Human | Esophagus | ESCC | 1.59e-14 | 2.68e-01 | 0.1131 |
| 1659 | DHX8 | P10T-E | Human | Esophagus | ESCC | 5.32e-10 | 1.11e-01 | 0.116 |
| 1659 | DHX8 | P11T-E | Human | Esophagus | ESCC | 6.23e-14 | 3.25e-01 | 0.1426 |
| 1659 | DHX8 | P12T-E | Human | Esophagus | ESCC | 3.23e-15 | 3.06e-01 | 0.1122 |
| 1659 | DHX8 | P15T-E | Human | Esophagus | ESCC | 6.06e-22 | 4.16e-01 | 0.1149 |
| 1659 | DHX8 | P16T-E | Human | Esophagus | ESCC | 3.40e-14 | 2.00e-01 | 0.1153 |
| 1659 | DHX8 | P17T-E | Human | Esophagus | ESCC | 4.75e-06 | 1.89e-01 | 0.1278 |
| 1659 | DHX8 | P20T-E | Human | Esophagus | ESCC | 9.54e-12 | 1.80e-01 | 0.1124 |
| 1659 | DHX8 | P21T-E | Human | Esophagus | ESCC | 1.09e-14 | 2.94e-01 | 0.1617 |
| 1659 | DHX8 | P22T-E | Human | Esophagus | ESCC | 1.16e-10 | 2.64e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Stomach | WIM |  |
| Stomach | SIM |  |
| Liver | NAFLD |  |
| Liver | Cirrhotic |  |
| Liver | HCC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:003298416 | Esophagus | ESCC | protein-containing complex disassembly | 151/8552 | 224/18723 | 3.45e-11 | 1.15e-09 | 151 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
| GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:002241112 | Liver | HCC | cellular component disassembly | 282/7958 | 443/18723 | 1.02e-19 | 1.38e-17 | 282 |
| GO:007182622 | Liver | HCC | ribonucleoprotein complex subunit organization | 159/7958 | 227/18723 | 3.14e-17 | 3.06e-15 | 159 |
| GO:003298411 | Liver | HCC | protein-containing complex disassembly | 138/7958 | 224/18723 | 5.59e-09 | 1.46e-07 | 138 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:002241119 | Oral cavity | OSCC | cellular component disassembly | 283/7305 | 443/18723 | 9.57e-27 | 3.37e-24 | 283 |
| GO:007182620 | Oral cavity | OSCC | ribonucleoprotein complex subunit organization | 152/7305 | 227/18723 | 1.05e-17 | 1.01e-15 | 152 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHX8 | SNV | Missense_Mutation | c.772N>G | p.Pro258Ala | p.P258A | Q14562 | protein_coding | tolerated(0.54) | benign(0.01) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| DHX8 | SNV | Missense_Mutation | c.2476N>C | p.Asp826His | p.D826H | Q14562 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DHX8 | SNV | Missense_Mutation | c.2569N>T | p.Pro857Ser | p.P857S | Q14562 | protein_coding | deleterious(0.01) | probably_damaging(0.992) | TCGA-AN-A041-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DHX8 | SNV | Missense_Mutation | novel | c.765C>A | p.Asp255Glu | p.D255E | Q14562 | protein_coding | tolerated(0.56) | benign(0.001) | TCGA-E9-A1N9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DHX8 | SNV | Missense_Mutation | novel | c.812N>T | p.Lys271Ile | p.K271I | Q14562 | protein_coding | tolerated(0.12) | benign(0.159) | TCGA-JL-A3YX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHX8 | insertion | Nonsense_Mutation | novel | c.2083_2084insGCAACTAGAGGAC | p.Asp695GlyfsTer3 | p.D695Gfs*3 | Q14562 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DHX8 | insertion | Frame_Shift_Ins | novel | c.2085_2086insCTTAGGTTGAG | p.Val696LeufsTer10 | p.V696Lfs*10 | Q14562 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| DHX8 | insertion | Frame_Shift_Ins | novel | c.1719_1720insATTAATG | p.Leu574IlefsTer9 | p.L574Ifs*9 | Q14562 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DHX8 | deletion | Frame_Shift_Del | novel | c.1942delN | p.Phe648LeufsTer14 | p.F648Lfs*14 | Q14562 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DHX8 | SNV | Missense_Mutation | novel | c.428N>C | p.Val143Ala | p.V143A | Q14562 | protein_coding | tolerated(0.78) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |